NASDAQ:AKAO

Achaogen Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Add
Compare
Today's Range N/A
50-Day Range
$0.11
$0.11
52-Week Range N/A
VolumeN/A
Average Volume3.34 million shs
Market Capitalization$7.03 million
P/E RatioN/A
Dividend YieldN/A
Beta0.78

Receive AKAO News and Ratings via Email

Sign-up to receive the latest news and ratings for Achaogen and its competitors with MarketBeat's FREE daily newsletter.


Achaogen logo

About Achaogen

Achaogen, Inc., a late-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibacterial treatments against multi-drug resistant (MDR) gram-negative infections in the United States. The company is principally developing plazomicin for the treatment of serious bacterial infections, including urinary tract infections, blood stream infections, and other infections due to MDR enterobacteriaceae comprising carbapenem-resistant enterobacteriaceae. It is also involved in the development of antibacterial candidate C-Scape, an orally-administered combination of clavulanate and ceftibuten, which targets serious bacterial infections due to expanded spectrum beta-lactamases producing enterobacteriaceae; and therapeutic antibody discovery program. The company has license and collaboration agreements with Thermo Fisher Scientific, Inc. to develop and commercialize an assay to support plazomicin; Crystal Biosciences, Inc. to discover monoclonal antibodies against multiple targets; Ionis Pharmaceuticals, Inc. for certain patents relating to aminoglycoside antibacterial compounds and related know-how to develop and commercialize certain novel aminoglycoside antibacterial compounds; and Hovione Limited to manufacture the active pharmaceutical ingredient for plazomicin. The company was incorporated in 2002 and is based in South San Francisco, California.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.13 out of 5 stars

Analyst Opinion: 0.0Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Achaogen (NASDAQ:AKAO) Frequently Asked Questions

What stocks does MarketBeat like better than Achaogen?

Wall Street analysts have given Achaogen a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Achaogen wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

How were Achaogen's earnings last quarter?

Achaogen Inc (NASDAQ:AKAO) issued its quarterly earnings data on Monday, August, 6th. The biopharmaceutical company reported ($1.11) earnings per share for the quarter, missing analysts' consensus estimates of ($0.92) by $0.19. The biopharmaceutical company had revenue of $2.56 million for the quarter, compared to the consensus estimate of $1.49 million. Achaogen had a negative net margin of 2,136.94% and a negative trailing twelve-month return on equity of 357.49%.
View Achaogen's earnings history
.

Who are Achaogen's key executives?

Achaogen's management team includes the following people:
  • Mr. Blake Wise, CEO & Director (Age 48)
  • Mr. Gary Loeb, Gen. Counsel, Corp. Sec. & Chief Compliance Officer (Age 49)
  • Ms. Zeryn Sarpangal, CFO and Principal Financial & Accounting Officer (Age 39)
  • Ms. Elizabeth Bhatt, Chief Bus. Officer & COO (Age 50)
  • Ms. Jeannie Lloyds, VP of Sales

What other stocks do shareholders of Achaogen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Achaogen investors own include Intelsat (I), Bank of America (BAC), Fossil Group (FOSL), Associated British Foods (ABF), Chaarat Gold (CGH), AMC Entertainment (AMC), First Data (FDC), Ciena (CIEN), Cypress Semiconductor (CY) and Synergy Pharmaceuticals (SGYP).

What is Achaogen's stock symbol?

Achaogen trades on the NASDAQ under the ticker symbol "AKAO."

How much money does Achaogen make?

Achaogen has a market capitalization of $0.00 and generates $8.73 million in revenue each year. The biopharmaceutical company earns $-186,510,000.00 in net income (profit) each year or ($3.70) on an earnings per share basis.

How many employees does Achaogen have?

Achaogen employs 206 workers across the globe.

What is Achaogen's official website?

The official website for Achaogen is www.achaogen.com.

Where are Achaogen's headquarters?

How can I contact Achaogen?

Achaogen's mailing address is 1 TOWER PLACE SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The biopharmaceutical company can be reached via phone at 650-800-3636 or via email at [email protected].


This page was last updated on 9/23/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.